Danaher Corporation vs Main Street Capital Corporation — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Main Street Capital Corporation trades at $53.19 (market cap $4.94B). The key difference: Danaher Corporation is far larger — about 28.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.25%). Which is the better fit depends on your goals.
| DHR | MAIN | |
|---|---|---|
Market Cap | $140.88B | $4.94B |
Sector | Health | Financials |
52-Week High | $242.05 | $67.54 |
52-Week Low | $161.91 | $49.63 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 8.25% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Main Street Capital (MAIN) trades at $52.51, down 0.62% on the day, with a bullish technical signal from moving averages. The company reported a net income margin of 81.08% for 2025, though revenue dipped to $592M from $601M in 2024. Recent news highlights MAIN's premium valuation among internally managed BDCs and a consistent dividend history, with the latest quarterly earnings showing a mix of beats and misses against expectations.
The outlook is supported by a consensus price target of $57.75, implying upside, but risks include softening earnings and negative operating cash flow. The stock offers a high yield, but investors should weigh the sustainability of dividends against rising expenses and a higher share count noted in recent analysis.
Trailing returns across standard periods
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →